Pharming Group NV ADR(PHAR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 86.98 | EPS (ttm) | 0.12 | Insider Own | - | Shs Outstand | 70.8M | Perf Week | -3.65% |
| Market Cap | 0.77B | Forward P/E | 40.94 | EPS next Y | 15.31% | Insider Trans | - | Shs Float | - | Perf Month | -12.39% |
| Enterprise Value | 0.73B | PEG | 0.37 | EPS next Q | 0.11 | Inst Own | 4.37% | Short Float | - | Perf Quarter | -15.5% |
| Income | 0.01B | P/S | 2.09 | EPS this Y | 473% | Inst Trans | 26.12% | Short Ratio | 1.75 | Perf Half Y | -25.43% |
| Sales | 0.37B | P/B | 2.98 | EPS next 5Y | 109.28% | ROA | 2% | Short Interest | 0.03M | Perf YTD | -38.77% |
| Book/sh | 3.63 | P/C | 4.84 | EPS past 3/5Y | -41.84% -41.23% | ROE | 3.77% | 52W High | -49.3% ($21.34) | Perf Year | -26.29% |
| Cash/sh | 2.24 | P/FCF | 29.81 | Sales past 3/5Y | 22.4% 12.25% | ROIC | 2.44% | 52W Low | 12.47% ($9.62) | Perf 3Y | -16.77% |
| Dividend Est. | - | EV/EBITDA | 21.33 | EPS Y/Y TTM | 220.58% | Gross Margin | 84.83% | Volatility(W/M) | 4.79% 3.74% | Perf 5Y | 6.08% |
| Dividend TTM | - | EV/Sales | 2.01 | Sales Y/Y TTM | 7.44% | Oper. Margin | 6.1% | ATR (14) | 0.52 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.31 | EPS Q/Q | -70.59% | Profit Margin | 2.49% | RSI (14) | 41.09 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.01 | Sales Q/Q | -4.63% | SMA20 | -5.72% ($11.48) | Beta | -0.06 | Target Price | $30.5 |
| Payout | - | Debt/Eq | 0.49 | Earnings | 2026/7/30 | SMA50 | -10.37% ($12.07) | Rel Volume | 1.38 | Prev Close | $11.21 |
| Employees | - | LT Debt/Eq | 0.46 | EPS/Sales Surpr. | -68.25% -9.36% | SMA200 | -27.61% ($14.95) | Avg Volume(3M) | 0.01M | Price | $10.82 |
| IPO | 2020/12/23 | Option/Short | No/Yes | Trades | 204 | Volume | 19,681 | Change | -3.48% |
Company
PHAR is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 Pharming Group (PHAR) is a Netherlands-based biopharmaceutical company focused on treatments for rare diseases. It commercializes RUCONEST, a therapy for acute attacks of hereditary angioedema, and Joenja (leniolisib), a treatment for activated phosphoinositide 3-kinase delta syndrome (an ultra-rare immune disorder), primarily in the United States. The company is growing on the back of high gross margins and deep expertise in rare diseases. Listed in the U.S. as an ADR, the stock is accessible to global investors.
Over the past 1 year, on the lower side
49% below its 1-year high.
PHAR makes money exceptionally well
6.1% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +473.0% this year.
Tap to view numbers
The price looks about right
Trading at 87.0 times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -16.8% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 4.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
EWN 0.00%
FDTS 0.00%
IEUS 0.00%
GWX 0.00%
BAMD 0.00%Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
IHE 1.6B
FTXH 1.0B
PBPH 1.0B
PPH 995M
XPH 588MIt ranks #4 in the industry
Based on market cap of $766M.
PHAR $766M PER 87.0
VRTX $132B PER 30.2
REGN $82B PER 19.6
ARGX $62B PER 37.8
FAQ
What kind of company is PHAR?
PHAR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PHAR?
The market cap of PHAR is approximately $766M, ranking 2,859 within its sector.
What is the P/E ratio of PHAR?
PHAR has a P/E ratio of approximately 87.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for PHAR?
PHAR has recorded a 52-week high of $21.34 and a low of $9.62.
